Today, the last trading day of the month, there are in total 51,241,791 shares and votes in Active Biotech.
Lund, June 30, 2008
Active Biotech AB (publ)
For further information, please contact:
Hans Kolam, CFO
Tel: +46 (0)46 19 20 44
E-mail: hans.kolam@activebiotech.com
Cecilia Hofvander, Manager Corporate Communications
Tel: +46 (0)46 19 11 22
About Active Biotech
Active Biotech AB (OMX Nordic: ACTI) is a biotechnology company focusing on research and development of pharmaceuticals. Active Biotech has a strong R&D portfolio with pipeline products focused on autoimmune/inflammatory diseases and cancer. Most advanced projects are laquinimod, an orally administered small molecule with unique immunomodulatory properties for the treatment of multiple sclerosis, as well as ANYARA for use in cancer targeted therapy, primarily renal cancer. Further key projects in clinical development comprise the three orally administered compounds TASQ for prostate cancer, 57-57 for SLE and RhuDex® for RA.
Active Biotech is required under the Financial Instruments Trading Act to make the information in this press release public. The information was submitted for publication at 8:30 a.m.CET on June 30, 2008.
Active Biotech AB
PO Box 724, 220 07 Lund
Sweden
Tel +46 (0)46-19 20 00
Fax +46 (0)46-19 20 50